CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Sees Significant Increase in Short Interest

Key Points

• Short interest surged 136.4% to 3.45 million shares as of October 15, representing 7.0% of CAMP4 Therapeutics’ outstanding shares and a 10.1-day days-to-cover ratio.
• The stock fell 2.4% to $3.81, while the company reported a quarterly loss of $0.58 per share—well below the $0.24 consensus estimate—and revenue of $1.78 million.
• Despite recent insider selling and ongoing losses, institutional investors initiated sizable positions and analysts maintained a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $10.44.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 3,450,760 shares, a growth of 136.4% from the September 30th total of 1,459,951 shares. Currently, 7.0% of the shares of the company are short sold. Based on an average daily trading volume, of 342,939 shares, the days-to-cover ratio is presently 10.1 days.

CAMP4 Therapeutics Stock Down 2.4%

NASDAQ:CAMP traded down $0.10 during trading hours on Friday, hitting $3.81. 19,894 shares of the stock traded hands, compared to its average volume of 202,625. The company has a market cap of $238.76 million, a price-to-earnings ratio of -1.64 and a beta of 0.27. CAMP4 Therapeutics has a 1 year low of $2.90 and a 1 year high of $7.75. The stock has a 50 day moving average price of $3.90 and a 200 day moving average price of $4.25.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Equities analysts forecast that CAMP4 Therapeutics will post -0.68 earnings per share for the current fiscal year.

Insider Transactions at CAMP4 Therapeutics

In related news, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director owned 2,033,270 shares of the company's stock, valued at $8,214,410.80. The trade was a 16.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard Young acquired 16,378 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director directly owned 186,388 shares of the company's stock, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. Company insiders own 21.69% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CAMP. Jupiter Topco LLC bought a new stake in CAMP4 Therapeutics in the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth about $25,647,928. Trails Edge Capital Partners LP purchased a new position in shares of CAMP4 Therapeutics during the second quarter valued at approximately $8,446,935. BlackRock Inc. purchased a new position in CAMP4 Therapeutics during the 2nd quarter valued at $7,185,000. Finally, SummitTX Capital L.P. bought a new position in shares of CAMP4 Therapeutics in the first quarter worth about $1,497,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CAMP. Chardan Capital reduced their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, September 29th. Zacks Research raised shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Finally, UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $10.44.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company's approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.